# US 2020/0369765 A1 · Siglec-9-neutralizing antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369765 A1
- Document ID: US20200369765A1
- Status: Published application
- Kind: A1
- Application number: 16/629,588
- Filed: 2018-07-09
- Published: 2020-11-26
- Earliest claimed: 2017-07-10
- Assignees: Innate Pharma
- Applicants: Innate Pharma
- Inventors: STÉPHANIE CORNEN; BENJAMIN ROSSI; NICOLAI WAGTMANN; LAURENT GAUTHIER
- Web page: https://patentgrep.com/patent/US20200369765A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 39/001129: {Molecules with a "CD" designation not provided for elsewhere}
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/54: F(ab')2
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.

## Claims

### Claim at position 1

1-53. (canceled)

### Claim 54

An agent that binds a human Siglec-9 polypeptide and is capable of neutralizing the inhibitory activity of a Siglec-9 polypeptide expressed by a human NK cell, wherein the agent comprises an antigen binding domain comprising a heavy chain variable region (VH) and a light chain variable region (VL) combination selected from the group consisting of:
a VH comprising a CDR1, 2 and 3 of the VH domain having the amino acid sequence shown in SEQ ID NO: 15 and a FR1, 2 and 3 of a human IGHV1-69 (or optionally IGHV1-46) gene segment, and a VL comprising a CDR1, 2 and 3 of the VL domain having the amino acid sequence shown in SEQ ID NO: 16 and a FR1, 2 and 3 of a human IGKV-33 gene segment;
a VH comprising a CDR1, 2 and 3 of the VH domain having the amino acid sequence shown in SEQ ID NO: 17 and a FR, 2 and 3 of a human IGHV1-69 (or optionally IGHV1-46) gene segment, and a VL comprising a CDR1, 2 and 3 of the VL domain having the amino acid sequence shown in SEQ ID NO: 18 and a FR1, 2 and 3 of a human IGKV1-33 gene segment;
a VH comprising a CDR1, 2 and 3 of the VH domain having the amino acid sequence shown in SEQ ID NO: 19 and a FR1, 2 and 3 of a human IGHV7-4-1 gene segment, and a VL comprising a CDR1, 2 and 3 of the VL domain having the amino acid sequence shown in SEQ ID NO: 20 and a FRI, 2 and 3 of a human IGKV7-3 gene segment; a VH comprising a CDR1, 2 and 3 of the VH domain having the amino acid sequence shown in SEQ ID NO: 21 and a FR1, 2 and 3 of a human IGHV7-4-1 gene segment (optionally in combination with a IGHJ6 gene segment), and a VL comprising a CDR1, 2 and 3 of the VL domain having the amino acid sequence shown in SEQ ID NO: 22 and a FR1, 2 and 3 of a human IGKV1-39 gene segment;
a VH comprising an amino acid sequence at least 70% identical to the amino acid sequence of the mAbA H0, H1, H2 or H3 variable domain shown in SEQ ID NOS: 170, 171, 172 and 173, respectively, and a VL comprising an amino acid sequence at least 70% identical to the amino acid sequence of the mAbA L0, L1 or L2 variable domain shown in SEQ ID NOS: 174, 175 and 176, respectively;
a VH comprising an amino acid sequence at least 70% identical to the amino acid sequence of the mAbB H0, H1, H2, H3, H4 or H5 variable domain shown in SEQ ID NOS: 177, 178, 179, 180, 181 and 182, respectively, and a VL comprising an amino acid sequence at least 70% identical to the amino acid sequence of the mAbB L0, L1 or L2 variable domain shown in SEQ ID NOS: 183, 184 and 185, respectively;
a VH comprising an amino acid sequence at least 70% identical to the amino acid sequence of the mAbC H0, H1, H2 or H3 variable domain shown in SEQ ID NOS: 192, 193, 194 and 195, respectively, and a VL comprising an amino acid sequence at least 70% identical to the amino acid sequence of the mAbC L0 or L1 variable domain shown in SEQ ID NOS: 196 and 197, respectively; a VH comprising an amino acid sequence at least 70% identical to the amino acid sequence of the mAbD H0, H1 or H2 variable domain shown in SEQ ID NOS: 186,187 and 188, respectively, and a VL comprising an amino acid sequence at least 70% identical to the amino acid sequence of the mAbD L0, L1 or L2 variable domain shown in SEQ ID NOS: 189, 190 and 191, respectively.

### Claim 55 (depends on 54)

The agent of claim 54, wherein the agent or antibody is a human or humanized antibody or is a monoclonal antibody or antibody fragment capable of bivalent binding to Siglec-9 polypeptides.

### Claim 56 (depends on 54)

The agent of claim 54, wherein the antibody lacks the ability to bind to the CD16 human Fcγ receptor.

### Claim 57 (depends on 54)

The agent of claim 54, wherein the antibody lacks the ability to bind to human CD16A, CD16B, CD32A, CD32B and CD64.

### Claim 58 (depends on 54)

A pharmaceutical composition comprising an antibody or agent according to claim 54 and a pharmaceutically acceptable carrier.

### Claim 59 (depends on 54)

A nucleic acid encoding a heavy and/or light chain of an antibody or antigen binding domain of claim 54.

### Claim 60 (depends on 54)

A recombinant host cell producing the antibody or antigen binding domain of claim 54.

### Claim 61 (depends on 54)

A method for the treatment of a disease in a patient in need thereof, the method comprising administering to said patient an effective amount of an antibody of claim 54 or a composition thereof.

### Claim 62 (depends on 61)

The method of claim 61, wherein said disease is cancer, optionally a cancer that is characterized by expression of ST3GAL1 and/or ST3GAL6 enzymes.

### Claim 63 (depends on 54)

A method for modulating CD56dim NK cells and/or CD56bright NK cells and/or CD8+ T cells in a subject the method comprising administering to said subject an effective amount of an antibody of claim 54.

### Claim 64 (depends on 54)

An in vitro method for modulating the activity of monocyte-derived cells and/or lymphocytes, optionally CD56dim NK cells, CD56bright NK cell and/or CD8+ T cells, the method comprising bringing onocyte-derived cells and/or lymphocytes expressing Siglec 7 and/or Siglec-9 into contact with an antibody of claim 54.

### Claim 65 (depends on 54)

An in vitro method for assessing the activity of NK cells from a subject having disease, the method comprising obtaining a biological sample from a subject comprising NK cells, bringing said cells into contact with an antibody of claim 54 and assessing whether the antibody modulate the activity of the NK cells.

### Claim 66 (depends on 54)

A method for identifying lymphocytes, optionally CD56dim NK cells, CD56bright NK cells and/or CD8+ T cells, the method comprising obtaining a biological sample from a subject comprising cells, bringing said cells into contact with an antibody of claim 54 and assessing whether the antibody binds to the cells.
